Skip to main content

Company News

  • August 31, 2021

    True Direct Quantification of Salmonella

    Salmonella detection has been a main-stay requirement in the food industry to prevent foodborne illness. While enrichment-based assays for the Presence / Absence detection of food pathogens are still vital to a safe and abundant global food supply, the food industry has longed for an easy to use and reliable diagnostic solution to accurately quantify levels of Salmonella to aid in process and product disposition decisions at the operational level.

  • June 01, 2021

    Cannabis Industry Can Now Avoid Costly Recalls

    bioMérieux, a world leader in the field of in-vitro diagnostics, today announced that it has received the first-ever cannabis-related Performance Tested MethodsSM (PTM) validation for the enumeration of yeasts and molds for its TEMPO® YM Assay (PTM 041001) by the AOAC INTERNATIONAL’s Emergency Response Validation (ERV) program.

  • February 24, 2021

    Innovative Technology Mitigates the Risk of Life-Threatening Toxins in Cannabis

    Invisible Sentinel, a bioMérieux Company, drove the innovation for the first method approved by the AOAC Research Institute Performance Tested Methods℠,(PTM) for the analysis of cannabis flower for pathogenic Aspergillus spp. within the marketplace, the assay is aptly named the GENE-UP® AspergillusPRO.

  • January 26, 2021

    Cannabis and Hemp are Safer for Consumers With New Microbial Testing Method Validations

    As the cannabis and hemp industry grow exponentially, the need for consumer safety is now more important than ever. Supporting that need for product and consumer safety, bioMérieux, a world leader in the field of in vitro diagnostics, received approval from the AOAC Research Institute Performance Tested Methods℠ (PTM) for the detection of Salmonella and STEC (Shiga toxin-producing E. coli) contaminants in cannabis flower and whole hemp flower utilizing GENE-UP® SLM2 (PTM 121802) and EHEC (PTM 121806) assays.

  • July 16, 2020

    Launch of BIOFIRE® MYCOPLASMA

    bioMérieux announces the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry.

Follow us on Socials for more news!